The Indian subsidiary of French pharma major Sanofi has received marketing authorization for Rezurock (belumosudil tablets) in India.

Sanofi Healthcare India has obtained marketing authorization for Rezurock, a drug for treating Chronic graft versus host ...

The latest health news covers topics such as the Trump administration's legal positions on transgender care, CDC research ...

Sanofi (NASDAQ:SNY – Free Report) by 25.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 314,180 shares of the company’s stock ...

Just days after taking back some of the stake held by L’Oréal, Sanofi has agreed to repurchase its own shares worth €2bn ($2.08bn) from other stakeholders. The French drugmaker said it had entered a ...

Sanofi, AstraZeneca and two leading trade groups want clarity around an appellate decision that called for Teva to delist ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025, Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, ...

French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

Experts at the 2025 Clinical Trial Supply Europe will explore supply chain challenges and the impact of AI on trials.